Arturo Loaiza-Bonilla, MD
Hematology & Oncology · Pennington, NJNPI 1972785947
Payments from drug & device makers
Across 519 payments — averaging $1679.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$309K
- Ipsen Biopharmaceuticals, Inc$107K
- AstraZeneca$80K
- Amgen$60K
- Genentech, Inc.$52K
- Eli Lilly$45K
- plus $219K from 33 others
Across 1 payment — averaging $61.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$62
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 172 | $309,467 |
| Ipsen Biopharmaceuticals, Inc | 58 | $106,719 |
| AstraZeneca | 61 | $79,955 |
| Amgen | 26 | $59,572 |
| Genentech, Inc. | 5 | $51,696 |
| Eli Lilly | 7 | $44,920 |
| Regeneron | 17 | $44,442 |
| Bayer | 45 | $44,022 |
| Daiichi Sankyo Inc. | 25 | $33,705 |
| Eisai Inc. | 23 | $24,781 |
| Taiho Oncology, Inc. | 5 | $20,486 |
| Bristol Myers Squibb | 11 | $12,906 |
| Astrazeneca UK Limited | 4 | $6,165 |
| Genentech USA, Inc. | 5 | $5,908 |
| Lexicon Pharmaceuticals, Inc. | 3 | $5,369 |
| Fresenius Kabi USA, LLC | 7 | $4,493 |
| Array Biopharma Inc | 3 | $4,432 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $2,800 |
| GSK | 2 | $2,192 |
| E.r. Squibb & Sons, L.L.C. | 10 | $2,058 |
| Seagen Inc. | 3 | $1,575 |
| Beigene, Ltd. | 1 | $1,500 |
| Deciphera Pharmaceuticals Inc. | 3 | $1,200 |
| Caris MPI, Inc. | 1 | $204 |
| Adaptive Biotechnologies Corporation | 2 | $143 |
| Philips North America LLC | 1 | $127 |
| Sanofi | 1 | $120 |
| Novocure Inc. | 1 | $116 |
| Gilead | 1 | $110 |
| Myriad Genetic Laboratories, Inc. | 3 | $101 |
| Lilly USA, LLC | 3 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Incyte Corporation | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Pfizer | 1 | $18 |
| Sobi, Inc | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Mirati Therapeutics, Inc. | 1 | $15 |
| Stemline Therapeutics Inc. | 1 | $15 |
How this compares
$871,483 in reported general payments places this provider in the 95th percentile of 362 hematology & oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Pennington
- Pamela CrilleyPennington$941K
- Bruno FangEast Brunswick$8.5M
- Charles FarberMorristown$4.6M
- Rajat BannerjiNew Brunswick$3.3M
- Eleonora TeplinskyParamus$2.6M
- Mohamad CherryMorristown$1.9M
- Evan NaylorManahawkin$1.3M
- James OrsiniBelleville$1.3M
- Eli KirshnerWestwood$1.2M
- Linda DanieuLivingston$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.